The Food and Drug Administration (FDA) has implemented a new artificial intelligence tool called Elsa across the agency, rolling it out several weeks earlier than initially planned. The tool aims to expedite clinical protocol and scientific reviews, potentially saving staff time and accelerating regulatory processes. While FDA leadership is enthusiastic about the technology’s promise, some employees have raised concerns that the deployment was rushed and the tool’s use might initially be limited in scope.
Related articles:
Latest AI Policy Updates from HHS and FDA
FDA Approval of AI-Powered Medical Diagnostics Ramps Up
Regulatory and Ethical Issues for AI Use in Medicine
